TY  - GEN
AU  - Yang,C H
AU  - Gonzalez-Angulo,A M
AU  - Reuben,J M
AU  - Booser,D J
AU  - Pusztai,L
AU  - Krishnamurthy,S
AU  - Esseltine,D
AU  - Stec,J
AU  - Broglio,K R
AU  - Islam,R
AU  - Hortobagyi,G N
AU  - Cristofanilli,M
TI  - Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits
SN  - 0923-7534
PY  - 2006///1107
KW  - Adult
KW  - Aged
KW  - Bone Neoplasms
KW  - drug therapy
KW  - Boronic Acids
KW  - pharmacology
KW  - Bortezomib
KW  - Breast Neoplasms
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Pleural Neoplasms
KW  - Protease Inhibitors
KW  - Pyrazines
KW  - Receptors, Estrogen
KW  - metabolism
KW  - Receptors, Progesterone
KW  - Soft Tissue Neoplasms
KW  - Survival Rate
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article
UR  - https://doi.org/10.1093/annonc/mdj131
ER  -